Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23228613 | 0.79 | CRBN (0.57) | CRBNGAAMEN1KMT2AOR51E2 | |
| SCHEMBL29347632 | 0.75 | CRBN (0.52) | CRBNMEN1KMT2AOR51E2FKBP5 | |
| SCHEMBL2916503 | 0.74 | — | — | |
| Morpholine SCHEMBL28108320 | 0.69 | OR51E2 (0.65) | CRBNGAAMEN1KMT2AKDM4E | |
| Morpholine SCHEMBL3637032 | 0.69 | GAA (0.52) | CRBNGAAMEN1KMT2AKDM4E | |
| SCHEMBL24537257 | 0.69 | CRBN (0.39) | CRBNGAAMEN1KMT2AKDM4E | |
| Morpholine SCHEMBL28275055 | 0.68 | CRBN (0.67) | CRBNGAAMEN1KMT2AKDM4E | |
| Morpholine SCHEMBL8785153 | 0.67 | GAA (0.48) | GAAMEN1KMT2AKDM4ECYP2C9 | |
| Morpholine SCHEMBL27350345 | 0.66 | GAA (0.52) | CRBNGAAMEN1KMT2AKDM4E | |
| SCHEMBL269755 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CRBN 115/4885GAA 1681/4885MEN1 1630/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CRBN 115/4885GAA 1681/4885MEN1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.